Further strengthens core R&D areas of autoimmune and allergic diseases Provides full control of brain-penetrant BTK inhibitor SAR442168 in multiple sclerosis (MS), making commercialization more efficient and eliminating future royalty payments Allows expansion of SAR442168 development program into other central … Read the full press release
Posted in Business, France, Healthcare, Investment, News, Pharma & Biotech
Tagged acquisition, allergic diseases, Arnaud Delepine, Ashleigh Koss, autoimmune diseases, biopharmaceutical, BofA Securities, Bruton tyrosine kinase, BTK inhibitor, BTK inhibitor ‘168, Centerview Partners LLC, Christopher Chai, commercialization, Cooley LLP, Eva Schaefer-Jansen, Evercore, Fara Berkowitz, Felix Lauscher, Gotshal & Manges LLP, John Reed M.D. Ph.D., Martin Babler, MS, multiple sclerosis, Nicolas Kressmann, pathophysiology, Paul Hudson, Paul Laland, Pharmaceutical, Principia, Principia Biopharma, PRN473 Topical, rilzabrutinib, Sanofi, SAR442168, Suzanne Greco, Weil, Yvonne Naughton
Sanofi to provide Plaquenil® (hydroxychloroquine) wherever possible, while securing appropriate supply levels for current approved indications; The company already increased its production capacity by 50% and is on track to further increase production over the coming months; Ongoing global clinical … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech, Science, Society, Technology
Tagged coronavirus, COVID-19, donation, hydroxychloroquine, Paul Hudson, Plaquenil, Sanofi
(PRESS RELEASE) PARIS and LEXINGTON, MA, U.S.A, 27-Mar-2020 — /EuropaWire/ — Sanofi Pasteur collaborates with Translate Bio (NASDAQ: TBIO) to develop a novel mRNA vaccine for COVID-19. Both companies will jointly investigate multiple candidates with the goal of advancing an … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech, Science
Tagged BARDA, Biomedical Advanced Research and Development Authority, COVID-19, David Loew, infectious diseases, messenger RNA, mRNA, novel mRNA vaccine, pandemic response, Ronald Renaud, Sanofi, Sanofi Pasteur, SARS-CoV-2 vaccine candidates, therapeutics, Translate Bio, vaccines
PARIS, 04-Oct-2018 — /EuropaWire/ — Sanofi has completed the previously announced divestment of its European generics business Zentiva to Advent International (Advent) effective September 30. The transaction was finalized ahead of schedule for €1,9 billion (enterprise value). Sanofi announced the beginning … Read the full press release
Posted in Business, France, Pharma & Biotech
Tagged Advent, divestment, generics, Sanofi, Zentiva
A plan taking place in almost 80 countries Subscription per five shares entitle the employee to one matching share[1] PARIS, 12-Jun-2018 — /EuropaWire/ — Sanofi launches today “Action 2018”, a worldwide stock purchase plan reserved for its employees. In doing such a … Read the full press release
Posted in France, Investment, Management, Pharma & Biotech
Tagged biopharma, Employees, health, Sanofi, shares, stock purchase plan, stock_purchase
Results showed Dupixent demonstrated a significant improvement in multiple asthma endpoints in two Phase 3 clinical trials in a broad population of patients with uncontrolled asthma, irrespective of minimum baseline eosinophil levels or other biomarkers of Type 2 inflammation Greater … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged asthma, corticosteroids, Dupixent, New England Journal of Medicine, Sanofi
PARIS, 25-Apr-2018 — /EuropaWire/ — Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service with the company. He will be succeeded in the post … Read the full press release
Posted in France, Healthcare, Management, Pharma & Biotech
Tagged appointment, biopharmaceutical, Elias Zerhouni M.D., John C. Reed M.D. Ph.D., leadership, Management, Sanofi
PARIS, 26-Feb-2018 — /EuropaWire/ — Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), applicable to Sanofi’s proposed acquisition of Bioverativ Inc. (“Bioverativ”, NASDAQ: BIVV) has expired. On February 7, … Read the full press release
Posted in Business, France, Pharma & Biotech
Tagged acquisition, ANTITRUST, Bioverativ, Hart-Scott-Rodino Antitrust Improvements Act, Healthcare, HSRAct, Sanofi
Expands Sanofi’s presence in specialty care and strengthens leadership in rare diseases Adds leader in the growing hemophilia market and provides platform for expansion in other rare blood disorders Drives meaningful shareholder value with ROIC expected to exceed cost of … Read the full press release
First head-to-head randomized clinical trial comparing the efficacy and safety of Toujeo (insulin glargine 300 Units/mL) versus insulin degludec PARIS, 05-Dec-2017 — /EuropaWire/ — Sanofi’s Toujeo® met the primary study objective in the first large head-to-head clinical trial1, called BRIGHT study, … Read the full press release
Posted in France, Healthcare, Pharma & Biotech, Technology
Tagged insulin degludec, Riccardo Perfetti, Sanofi, The BRIGHT study, Toujeo®
PARIS, 05-Dec-2017 — /EuropaWire/ — Following a planned interim analysis, the Independent Data Monitoring Committee (IDMC) for the phase III Cdiffense clinical trial program concluded that the probability that the study will meet its primary objective is low. Based on this, Sanofi has … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged Clostridium difficile vaccine, Sanofi, Sanofi Pasteur
LONDON, 01-Dec-2017 — /EuropaWire/ — On December 5-6, 2017, 200 high-level experts from government, academia, biopharmaceutical developers and patient organisations convene in London (UK) to address the mounting challenge of accessibility and patient access to high-value, high-cost medical therapies. The … Read the full press release
Posted in Government, Healthcare, News, Non Profit, Pharma & Biotech, Science, Society, United Kingdom
Tagged academia, Aetna, analytica|LASER, auto-immune diseases, biopharmaceutical, biopharmaceutical developers, Cancer, deadly HIV epidemic, Dr. Harold Paz, Dr. Olivier Brandicourt, Dr. Sarah Garner, drug developers, drug policy, EURORDIS-Rare Diseases Europe, French HAS, global health systems sustainability, government, health ministries, health systems, Healthcare, high-cost medical therapies, high-value medicines, Julia Corner, life-saving drugs, London School of Hygiene and Tropical Medicine, medicine access, medicine accessibility, National Institute for Health and Care Excellence, not-for-profit event, patient access, patient organisations, Pharmaceutical, Prof Peter Piot, Prof. Dominique Le Guludec, Prof. Lucien Abenhaim, rare disease, rare diseases, Renaissance St Pancras Hotel, Sanofi, Sir Andrew Dillon, Ulrich Neumann, World Health Organization, Yann Le Cam
First study with a biologic to show benefit in severe steroid-dependent asthma population that enrolled patients regardless of blood eosinophil levels or any other Type 2 biomarkers at baseline Pivotal program is first with a biologic to show consistent reductions … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged dupilumab, Sanofi, steroid-dependent asthma
PARIS, 10-Aug-2017 — /EuropaWire/ — Sanofi announced today that it filed a patent infringement suit against Merck Sharp & Dohme Corp. (“Merck”) on August 8, 2017 in the United States District Court for the District of New Jersey. In its suit Sanofi … Read the full press release
Posted in France, Pharma & Biotech
Tagged Merck Sharp & Dohme Corp., Sanofi
PARIS, 04-Jan-2017 — /EuropaWire/ — Sanofi announced today that Soliqua™ 100/33 (insulin glargine 100 Units/mL & lixisenatide* 33 mcg/mL injection) is now available by prescription in U.S. pharmacies. Soliqua 100/33 is indicated for the treatment of adults with type 2 … Read the full press release
Both companies will become global leaders in two different sectors of the pharmaceutical market Paris (France) and Ingelheim (Germany), 03-Jan-2017 — /EuropaWire/ — Sanofi and Boehringer Ingelheim confirmed today that the strategic transaction signed in June 2016, which consists of an … Read the full press release
PARIS, 03-Jan-2017 — /EuropaWire/ — Sanofi and its vaccines global business unit Sanofi Pasteur confirmed today the end of their vaccine joint-venture with MSD (known as Merck & Co. Inc., in the United States and Canada), Sanofi Pasteur MSD (SPMSD). … Read the full press release
Posted in Business, France, Healthcare, Pharma & Biotech
Tagged Merck & Co. Inc., MSD, Sanofi, Sanofi Pasteur, vaccine joint-venture
PARIS, 04-Oct-2016 — /EuropaWire/ — Sanofi today announced the appointment of Alan Main as Executive Vice President Consumer HealthCare, effective October 1st, 2016. Mr. Main will be a member of the Executive Committee and lead a newly created Consumer Healthcare … Read the full press release
Posted in Business, France, Healthcare, Management, Pharma & Biotech
Tagged Alan Main, Consumer HealthCare, Olivier Brandicourt, Sanofi
PARIS, 31-Mar-2016 — /EuropaWire/ — Sanofi announced today the appointment of Dr. Yong-Jun Liu as Head of Research, Global R&D, effective April 1, 2016. He will report to Dr. Elias Zerhouni, President, Global R&D. Dr. Liu is one of the world’s … Read the full press release
Posted in France, Management, Pharma & Biotech
Global introduction of the first Dengue Vaccine gains further momentum with this third approval in a row in an endemic country – With 1.4 million dengue cases reported this year, Brazil stands to gain tremendous value from this new dengue … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged Dengue, Dengue Vaccine, Dengvaxia®, Sanofi, Sanofi Pasteur
LixiLan met primary endpoint showing superior reduction in HbA1c vs Insulin Glargine alone PARIS, 14-9-2015 — /EuropaWire/ — Sanofi announced today that the LixiLan-L Phase III clinical trial met its primary endpoint in patients with type 2 diabetes treated with insulin glargine with … Read the full press release
Posted in France, Healthcare, Pharma & Biotech, Science
Tagged glargine, insulin, LixiLan-L Phase III clinical trial, metformi, Sanofi, type 2 diabetes
Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa®(vandetanib) from AstraZeneca Paris, France, 30-7-2015 — /EuropaWire/ — Sanofi and its subsidiary Genzyme announced today that it has entered into a definitive agreement with AstraZeneca to acquire Caprelsa® (vandetanib), a … Read the full press release
Posted in Business, France, Healthcare, Management, Pharma & Biotech
Tagged AstraZeneca, Caprelsa® (vandetanib), Genzyme, Luke Miels, Sanofi
Sanofi and Regeneron Launch Major New Immuno-Oncology Collaboration Companies agree to jointly advance PD-1 and other new immuno-oncology antibodies – Sanofi commits to an initial investment of up to $2.17 billion in the exclusive collaboration, including $640 million in upfront payments to Regeneron … Read the full press release
Investigational Enzyme Replacement Therapy to Treat Non-Neurological Manifestations which characterize Niemann-Pick Type B PARIS, 5-6-2015 — /EuropaWire/ — Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olipudase alfa. … Read the full press release
Posted in France, Pharma & Biotech, Science
Tagged Breakthrough Therapy, Genzyme, Niemann-Pick Type B, olipudase alfa, Richard Peters, Sanofi, sphingomyelin, US FDA
PARIS, 9-3-2015 — /EuropaWire/ — Sanofi today announced the appointment of Robert Castaigne as Chairman of its Audit Committee. Mr. Castaigne succeeds Dr. Klaus Pohle who has chaired Sanofi’s Audit Committee since 2004. This appointment is effective as of the Sanofi Board … Read the full press release
Posted in Business, France, Healthcare, Management, Pharma & Biotech
Tagged Dr. Klaus Pohle, global healthcare leader, Robert Castaigne, Sanofi
Approval Establishes Genzyme’s MS Franchise in the U.S. with Two Approved Products; Follows Global Approvals PARIS, 17-11-2014 — /EuropaWire/ — Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration (FDA) has approved LemtradaTM (alemtuzumab) for … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged David Meeker, Dr. Timothy Coetzee, Edward Fox, FDA, Genzyme, LemtradaTM (alemtuzumab), M.D., multiple sclerosis (MS), Ph.D., Sanofi
Up to $200 Million Collaboration to Support Pioneering Science and New Treatments Paris and South San Francisco, CA, 18-9-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) and MyoKardia, Inc., a privately-held company leading the development of precision therapies for genetic … Read the full press release
In approximately 70 percent of patients, disability scores improved or remained stable for an additional two years beyond the two-year pivotal multiple sclerosis studies Approximately 70 percent of patients treated with Lemtrada did not receive a third course of treatment … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged Genzyme, Lemtrada™ (alemtuzumab) for multiple sclerosis, Sanofi
Only First-Line Oral Treatment for Adult Gaucher Disease Type 1 Paris, 22-8-2014 — /EuropaWire/ — Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has approved Cerdelga™ (eliglustat) capsules, the only … Read the full press release
First shipment marks a critical step in improving access to treatment worldwide Paris, France, and South San Francisco, United States, 19-8-2014 — /EuropaWire/ — Sanofi (Euronext: SAN and NYSE: SNY) and PATH today announced the delivery of the first large-scale batches of … Read the full press release
Initial focus on insulin-device combinations and care management services Paris and Minneapolis, Minn., 16-6-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) and Medtronic, Inc. (NYSE: MDT) today announced that they have signed a memorandum of understanding to enter into a … Read the full press release
Posted in Business, France, Healthcare, Pharma & Biotech, Society
Tagged d Pascale Witz, Diabetes, Medtronic, Omar Ishrak, Sanofi
Both doses of investigational drug sarilumab met all three co-primary endpoints New data include major clinical response rates and ACR20 scores at 52 weeks Paris and Tarrytown, NY, 16-6-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, … Read the full press release
Meta-analysis of three late-stage trials in people with type 2 diabetes shows decreases in risk of low blood sugar events of up to 31% at night-time compared with Lantus® All studies in the phase 3 “EDITION” clinical trial program, including a … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged fewer low blood sugar events, Geremia Bolli, Lantus®, Sanofi, Toujeo® consistently
Shan5™ is the first vaccine jointly developed by the Indian company and its parent company Sanofi Pasteur WHO’s decision allows for the purchase of Shan5™ by United Nations agencies Lyon, France, 7-5-2014 — /EuropaWire/ — Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: … Read the full press release
Appointment is a First for a Top 10 Biopharmaceutical Company Paris, France, 1-4-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) today announced the appointment of Anne C. Beal, M.D., MPH, to the newly created position of Chief Patient Officer. « … Read the full press release
Posted in Business, France, Management, Pharma & Biotech, Science
Tagged Chief Patient Officer at Sanofi, Dr. Anne C. Beal, Laurence Bollack, Pascale Witz, Sanofi, Sébastien Martel
Companies To Host Investor Conference Call on Alirocumab on March 31 at 9 a.m. EDT Paris, France and Tarrytown, NY, 28-3-2014 — /EuropaWire/ — Sanofi (EURONEXT : SAN and NYSE : SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data … Read the full press release
Paris, France, 31-1-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it filed a patent infringement suit against Eli Lilly and Company ( “Lilly”) on January 30, 2014 in the United States District Court for the District of Delaware. In … Read the full press release
Posted in France, Healthcare, Law, Pharma & Biotech
Tagged Eli Lilly, Lantus®, Lantus® SoloStar®, patent infringement suit, Sanofi
Paris, France, 30-1-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that RobecoSAM, which measures the performance of companies in terms of corporate social responsibility (CSR), has included Sanofi for the seventh consecutive year in the 2014 Sustainability Yearbook published this month. … Read the full press release
Paris, France, 21-11-2013 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the decision to halt all clinical trials and cancel plans for regulatory filings with its investigational JAK2 inhibitor, fedratinib (SAR302503). Following a thorough risk-benefit analysis, including consultation with the U.S. … Read the full press release
Paris, France, 12-11-2013 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) announces that it has successfully priced its offering of EUR 1 billion of notes, due 2023, bearing interest at an annual rate of 2.50%. The issue is drawn under the Company’s Euro … Read the full press release
Posted in Business, Financial, France, Healthcare, Investment, Pharma & Biotech, Science
Tagged bond, bookrunners, Citi, EURONEXT: SAN, HSBC, Laurence Bollack, NYSE: SNY, Sanofi, Santander GBM, Sébastien Martel, The Royal Bank of Scotland
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
